Tests BMS-986460 in men with advanced prostate cancer that stopped responding to hormone therapy
Tests the drug BMS-986460 for safety and early effects in men with advanced prostate cancer.
Plain-language title generated from the registry record
Registry title: A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
Key facts
- Where
- Montreal and Toronto, CanadaSee the 2 sites
- Phase
- Phase 1
Where in Canada
- MontrealMontreal, CanadaNot yet recruiting
- TorontoToronto, CanadaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Bristol-Myers Squibb
- Trial code
- NCT06067841EU 2024-513987-24-00
- Record updated
- 10 August 2026
- Original description
The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of BMS-986460 in men with Metastatic Castration-resistant Prostate Cancer.Read full original descriptionShow less
A Phase 1, Open-label Study of BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of BMS-986460 in men with Metastatic Castration-resistant Prostate Cancer.
Inclusion: Participant must have histologically or cytologically confirmed adenocarcinoma of the prostate; Participant must have an Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1; Participant must have prostate specific antigen (PSA) of ≥ 2 ng/mL at Screening; Participant must have progressed on androgen deprivation therapy (ADT) and at least one prior secondary hormonal therapy approved for castration-resistant prostate cancer (CRPC).
Exclusion: Participant must not have history of brain metastases; Participant must not have impaired cardiac function or clinically significant cardiac disease; Participant must not have any significant medical condition, including active or uncontrolled infection, psychiatric illness, or the presence of laboratory abnormalities, which places the participant at unacceptable risk or prevent participation in the study based on Investigator assessment; Other protocol-defined inclusion/exclusion criteria apply.